Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia

A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a d...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Valerio Guarente, Giovanni Martino, Erica Dorillo, Filomena De Falco, Chiara Rompietti, Daniele Sorcini, Mariangela Brogna, Valeria Cardinali, Stefano Ascani, Andrea Marra, Paolo Sportoletti
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Subjects:	T-cell lymphoma chronic lymphocytic leukemia venetoclax (BCL2 inhibitor) lymphomatoid papulosis (LyP) lymphomatoid papulosis treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/full